Skandinaviska Enskilda Banken AB publ Cuts Position in United Therapeutics Corporation $UTHR

Skandinaviska Enskilda Banken AB publ lessened its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 10.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 89,960 shares of the biotechnology company’s stock after selling 10,894 shares during the period. Skandinaviska Enskilda Banken AB publ owned about 0.20% of United Therapeutics worth $25,854,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. F m Investments LLC grew its stake in shares of United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after buying an additional 33 shares in the last quarter. HB Wealth Management LLC boosted its holdings in United Therapeutics by 2.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after acquiring an additional 35 shares during the period. Park Avenue Securities LLC grew its position in United Therapeutics by 1.7% in the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 39 shares in the last quarter. Headlands Technologies LLC grew its position in United Therapeutics by 1.5% in the first quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company’s stock valued at $828,000 after acquiring an additional 40 shares in the last quarter. Finally, First Financial Bankshares Inc raised its stake in shares of United Therapeutics by 0.3% during the first quarter. First Financial Bankshares Inc now owns 13,769 shares of the biotechnology company’s stock valued at $4,245,000 after purchasing an additional 42 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 4,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $475.33, for a total transaction of $1,901,320.00. Following the completion of the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $61,792.90. This represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $486.06, for a total transaction of $5,346,660.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $17,877,772.86. This represents a 23.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 578,435 shares of company stock valued at $252,731,147 over the last three months. Corporate insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald upped their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. UBS Group upped their price objective on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Oppenheimer lifted their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Bank of America increased their price target on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Finally, HC Wainwright upped their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Stock Down 0.5%

Shares of NASDAQ UTHR opened at $485.97 on Friday. The firm’s 50-day moving average price is $447.65 and its two-hundred day moving average price is $361.75. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $492.62. The stock has a market capitalization of $20.92 billion, a P/E ratio of 18.41, a P/E/G ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm earned $6.39 EPS. As a group, equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.